A joint research group of Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (medicine), Okayama University Hospital New Medical Research and Development Center, and Hayashihara announced on December 12th, 16, a new regulatory T cell "HOZOT" developed by Hayashihara. ) ”, Announced that it has succeeded in developing a technology for selectively transporting tumor-thawing virus preparations to cancer cells.
Peritoneal dissemination metastasis is a condition in which cancer cells spread from the primary tumor into the abdominal cavity as the cancer progresses, and is often resistant to systemic chemotherapy and has a poor prognosis.Currently, intraperitoneal chemotherapy for peritoneal dissemination metastasis is being performed, but clinical trials have not yet achieved sufficient improvement in survival.Therefore, there is a demand for more effective cancer directivity.
This time, the research group created HOZOT cells carrying an oncolytic virus by utilizing the selective intracellular invasion effect of a novel regulatory T cell "HOZOT" into cancer cells.We have developed a technology to selectively deliver oncolytic virus to cancer cells.HOZOT cells carrying oncolytic virus invade cancer cells and spread the virus by selectively delivering them to cancer cells, killing many cancer cells that have spread in the abdomen. It is said that it was proved by a model.
In the future, if HOZOT cells can be established from the blood of individual cancer patients, it will be possible to selectively deliver oncolytic virus to cancer cells suitable for each patient.This is expected to be a new therapeutic strategy for intractable peritoneal dissemination metastasis.
